$0.00
−60.53%Sep 8, 2026, 12:30 UTC
Surrozen submitted an Investigational New Drug application to the U.S. Food and Drug Administration for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema.
Source: